Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
GenMark Prices Public Offering of Common Stock
-
GenMark Prices Public Offering of Common Stock
-
GenMark Diagnostics (GNMK) to Offer Common Stock
-
GenMark Commences Public Offering of Common Stock
-
GenMark Commences Public Offering of Common Stock
-
GenMark Diagnostics (GNMK) PT Lowered to $9 at Canaccord Genuity, Following Announcement of CEO Transition
-
GenMark Diagnostics to Participate in Upcoming Investor Conferences
-
GenMark Diagnostics to Participate in Upcoming Investor Conferences
-
GenMark Diagnostics to Participate in the Canaccord Genuity Growth Conference
-
GenMark Diagnostics to Participate in the Canaccord Genuity Growth Conference
-
GenMark Diagnostics to Present at Upcoming Investor Conferences
-
GenMark Diagnostics (GNMK) PT Lowered to $9 at Canaccord Genuity
-
GenMark Diagnostics to Present at the Canaccord Genuity 38th Annual Growth Conference
-
GenMark Diagnostics to Present at the Canaccord Genuity 38th Annual Growth Conference
-
GenMark Diagnostics (GNMK) PT Raised to $9 at Canaccord Genuity
-
GenMark Diagnostics (GNMK) PT Lowered to $8 at Canaccord Genuity
-
GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
-
GenMark Diagnostics to Attend Canaccord Genuity’s 37th Annual Growth Conference
-
GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
-
GenMark Diagnostics to Present at the 36th Annual Canaccord Genuity Growth Conference
-
GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8
-
GenMark Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference
-
GenMark (GNMK) Prices Upsized 7.6M Offering at $9.84/Share
-
GenMark Diagnostics (GNMK) Sell-Off Buying Opp., Agreement Intact - Canaccord
-
Canaccord Genuity Lifts PT on GenMark Diagnostics (GNMK) to $18
-
Streetinsider.com's Hot Lunchtime Reads 01/15: (CMCSA) (TER) (MBI) (DELL) (STJ)
-
Canaccord Genuity Positive on GenMark Diagnostics (GNMK)
-
Canaccord Genuity Maintains a 'Buy' on GenMark Diagnostics (GNMK); Q2 Preview: Expecting Really Good Numbers
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Secondary Completed

